Blockchain Registration Transaction Record

Kairos Pharma's Prostate Cancer Therapy Shows 86% Clinical Benefit

Kairos Pharma reports 86% clinical benefit in Phase 2 prostate cancer trial for ENV-105. The therapy shows promise in restoring hormone responsiveness in resistant patients.

This development represents a potential breakthrough in treating metastatic castration-resistant prostate cancer, one of the most challenging forms of prostate cancer that has stopped responding to standard hormone therapies. For patients facing limited treatment options and poor prognoses, ENV-105's ability to restore hormone responsiveness and demonstrate high clinical benefit rates could significantly extend survival and improve quality of life. The therapy's mechanism of targeting CD105 to reverse drug resistance addresses a fundamental problem in cancer treatment that affects multiple cancer types, suggesting broader applications beyond prostate cancer. Successful development of this approach could transform treatment paradigms for resistant cancers and provide new hope for patients who have exhausted conventional options.